Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27908371)
Watch
English
KRAS Exon 2 Mutation
genetic variant
EXON 2 MUTATION
In more languages
edit
Statements
instance of
missense mutation
1 reference
stated in
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/variants/75
chromosome
human chromosome 12
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/variants/75
genomic start
25398208
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/variants/75
genomic end
25398329
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/variants/75
biological variant of
KRAS
1 reference
stated in
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/variants/75
positive therapeutic predictor for
vemurafenib
determination method
CIViC evidence level D
rating
CIViC 3-star trust rating
medical condition treated
colorectal cancer
statement disputed by
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/8367
stated in
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
regorafenib
determination method
CIViC evidence level B
rating
CIViC 1-star trust rating
medical condition treated
colorectal cancer
statement disputed by
Regorafenib in metastatic colorectal cancer.
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/87
stated in
Regorafenib in metastatic colorectal cancer.
negative therapeutic predictor for
erlotinib
medical condition treated
pancreatic carcinoma
statement disputed by
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/916
stated in
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
cetuximab
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
colorectal cancer
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/250
stated in
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
cetuximab
determination method
CIViC evidence level A
rating
CIViC 5-star trust rating
medical condition treated
colorectal cancer
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/993
stated in
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
erlotinib / gemcitabine combination therapy
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
medical condition treated
pancreatic cancer
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1219
stated in
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy
negative prognostic predictor for
pancreatic carcinoma
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/917
stated in
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
rectum cancer
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
statement disputed by
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/4052
stated in
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
colorectal cancer
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
statement disputed by
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer
1 reference
curator
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/2361
stated in
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer
Identifiers
CIViC variant ID
75
1 reference
stated in
CIViC database
retrieved
28 March 2022
reference URL
https://civic.genome.wustl.edu/links/variants/75
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
